Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

3 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.

Ixazomib-cyclophosphamide-dexamethasone combo effective for multiple myeloma

10 Aug 2018

The combination of ixazomib, cyclophosphamide and dexamethasone is well-tolerated and effective for newly diagnosed myeloma, a recent study has shown.

The phase 1/2 study included 48 patients newly diagnosed with multiple myeloma (median age 64.5 years; 52.1 percent male), of whom 45 (median age 64.0; 53.3 percent male) subsequently received the phase 2 dose. The maximum tolerated dose and the rate of complete or very good partial responses (VGPR) were the primary endpoints for the first and second phases of the study, respectively.

Majority of the patients (77 percent; n=37) reported at least a confirmed partial response, with 35 percent achieving a VGPR or better. The median time to response was 1.9 months, and the depth of response increased as participants received more cycles of therapy. The overall response rate at the end of four cycles was 71 percent.

The median progression-free (PFS) and overall (OS) survival were not reached for the whole study sample, while the 18-month PGS and OS rates were 81 percent and 96 percent. The 1-year OS was 100 percent.

Over a median of seven therapy cycles, 100 percent of the participants reported at least one adverse event of any grade. Grade 3 or 4 adverse events that were considered to be at least potentially associated to the therapy was observed in 88 percent of the participants.

The most common grade 2 adverse event included nausea, anaemia, neutropoenia, leukopoenia and lymphopoenia.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

3 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.